Production of mice containing binding proteins containing the VL domain

By introducing human light chain gene segments into mouse heavy chain loci, using somatic hypermutation and genetic modification technology, a binding protein with high affinity and diversity was created, and the immunoglobulin domain in the prior art was solved. The efficiency problem in antigen response has achieved efficient antigen binding ability.

CN113150121B9Active Publication Date: 2024-11-26REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110412459.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2010-08-02
Filing Date
2011-08-02
Publication Date
2024-11-26
Estimated Expiration
2031-08-02

AI Technical Summary

Technical Problem

The prior art is difficult to effectively utilize the immunoglobulin domain to create binding proteins with high affinity and diversity, especially in antigen responses, and it is difficult to achieve efficient modification and expression of immunoglobulin heavy chain loci.

Method used

By introducing human light chain gene segments, especially Vκ and Vλ segments, as well as Jκ and Jλ segments to mouse heavy chain loci, combining somatic cell hypermutation and genetic modification techniques, a human variable structure is created by introducing human light chain gene segments, especially Vκ and Vλ segments, as well as Jκ and Jλ segments to mouse heavy chain loci, the patient will have a combination of somatic cell hypermutation and genetic modification techniques. The immunoglobulin heavy chain of the domain ensures its expression in mice and produces high affinity binding proteins.

Benefits of technology

The expression of human variable domains in most IgG molecules is achieved, which improves antigen binding ability and diversity, ensuring that at least 50% of mouse IgG molecules contain human CDR3, and that most IgGs contain human Vλ or Vκ segment, significantly improving antigen binding affinity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113150121B9_ABST
    Figure CN113150121B9_ABST
Patent Text Reader

Abstract

Genetically modified mice and methods for making and using them are provided, wherein the mice include replacing all or substantially all immunoglobulin heavy chain V gene segments, D gene segments and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. A mouse is provided, which manufactures a conjugated protein comprising a light chain variable domain operably connected to a heavy chain constant region. A conjugated protein is provided, which contains an immunoglobulin light chain variable domain, which includes a light chain variable domain fused to a heavy chain constant region and hypermutated through a somatic cell. Modified cells, embryos and mice are provided, which encode sequences for making the conjugated protein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is an application numbered 201610124564.5, filed on August 2, 2011, Field of the Invention

[0002] Provided are immunoglobulin-like binding proteins comprising an immunoglobulin light chain variable binding protein.

[0003] background

[0004] Antibodies usually consist of a tetrameric structure with two identical heavy chains, each containing

[0005] In a typical antibody, V H With V L The domains associate to form a binding site for the target antigen.

[0006] There is a need in the art for binding proteins based on immunoglobulin structures, including immunoglobulin SUMMARY OF THE INVENTION

[0007] In one aspect, a binding protein is described that comprises an immunoglobulin variable domain, said

[0008] In one aspect, nucleic acid constructs, cells, embryos, mice and methods are provided for producing

[0009] In one aspect, a mouse is provided that comprises an immunoglobulin heavy chain locus, wherein the gene

[0010] In one aspect, a mouse is provided that includes an immunoglobulin heavy chain locus, wherein the gene

[0011] In one embodiment, the V L Segment is person V L In one embodiment,

[0012] In one embodiment, at least six human Vκ gene segments and at least one Jκ gene segment are used.

[0013] In one embodiment, the V L The segment is a human Vκ segment.

[0014] In one embodiment, the V L The segment is a human Vκ segment and includes 4-1, 5-2,

[0015] In one embodiment, the V L The segment is a human Vλ segment and comprises a human λ light chain gene

[0016] In one embodiment, the V L The segment contains a fragment of cluster B of the human lambda light chain locus

[0017] In one embodiment, the V L The segment comprises a human lambda light chain variable region sequence, which comprises

[0018] In one embodiment, the V L The segment comprises at least one gene segment of cluster B and

[0019] In one embodiment, the V L The segment contains hVλ3-1, 4-3, 2-8, 3-9,

[0020] In one embodiment, the hVλ comprises 13 to 28 or more hVλ.

[0021] In one embodiment, the V L The segment contains 29 to 40 hVλ.

[0022] In one embodiment, the Jκ is human and is selected from Jκ1, Jκ2, Jκ3, Jκ4,

[0023] In one embodiment, the V L The segment is a human Vλ segment, and the Jκ gene region

[0024] In a specific embodiment, the V L The segment spans from Vκ4-1 to Vκ2-40

[0025] In one embodiment, wherein V L The segment is a Vλ segment and there is no D H Segment Memory

[0026] In one embodiment, wherein the V gene segment is a Vκ gene segment and has no

[0027] In one embodiment, the mouse comprises a rearranged gene derived from V L Gene segment,

[0028] In one embodiment, the mouse comprises a B cell, wherein the B cell is derived from a B cell.

[0029] In one embodiment, at least 50% of all IgG molecules produced by the mouse comprise

[0030] In one embodiment, the mouse produces a binding protein comprising a first polypeptide and a second

[0031] In one embodiment, the mouse expresses a binding protein comprising:

[0032] In one aspect, a genetically modified mouse is provided that expresses a polypeptide consisting essentially of

[0033] In a specific embodiment, having C H The two identical polypeptides in the region have mouse

[0034] In a specific embodiment, having C L The two identical polypeptides in the region have mouse

[0035] In one embodiment, with C L The variable domain fused to the region is identical to the C H District Integration

[0036] In one embodiment, the endogenous mouse C H The variable domains fused to each other contain

[0037] In one embodiment, one or more of the V segments and J segments are human gene regions.

[0038] In one embodiment, with C L One or more variable domains fused to the

[0039] In one embodiment, the two identical first polypeptides have V L The gene segment was selected from

[0040] In one embodiment, mouse IgG includes binding proteins produced in response to antigen.

[0041] In one aspect, a mouse is provided wherein all or substantially all of the

[0042] In one embodiment, the V segment is a light chain V segment.

[0043] In one embodiment, the J segment is the J segment of a light chain.

[0044] In one embodiment, the variable region of the heavy chain is composed of no more than a V segment and a J segment.

[0045] In one embodiment, the variable region of the heavy chain is composed of no more than a V segment and a J segment.

[0046] In a specific embodiment, all or substantially all of the protein produced by the mouse in response to the antigen

[0047] In one aspect, a mouse is provided, which is manufactured in a cell culture medium comprising C H The first CDR3

[0048] In one embodiment, the V L Segment and J L The segment is a human gene segment.

[0049] In one aspect, a mouse is provided, which is produced in a culture medium containing C H The first polypeptide of the region comprises a first

[0050] In one embodiment, more than 80%, more than 90% or more than 95% of the first

[0051] In one embodiment, no more than two amino acids of the first CDR3 are derived from

[0052] In one embodiment, the V segment is a human V gene segment.

[0053] In one embodiment, the first and / or second CDR3 has at least one, two

[0054] In one embodiment, the first CDR3 is substantially derived from a human light chain V

[0055] In one aspect, a mouse is provided, which is produced without D H Amino acid sequence of gene segment

[0056] In one embodiment, the first and second V L Domains were independently selected from human and

[0057] In one aspect, a mouse is provided wherein all or substantially all of the

[0058] In one embodiment, the mouse C H The human V L The domain is

[0059] In one embodiment, the first and second persons V L The domains are not identical.

[0060] In one aspect, mice are provided wherein at least 10%, 20%, 30%, 40%, 50%,

[0061] In one embodiment, the second polypeptide is about 435-535 amino acids in length.

[0062] In one embodiment, in about 90% or more of the IgG produced by the mouse,

[0063] In one embodiment, in about 50% or more of the IgG produced by the mouse,

[0064] In one embodiment, the V domain of the second polypeptide is V L Domain.

[0065] In one aspect, a mouse is provided that expresses a light chain from a nucleotide sequence in its germline

[0066] In one embodiment, the mouse expresses the polyadenylation protein from an endogenous mouse heavy chain locus.

[0067] In one embodiment, the polypeptide comprises a V derived from a Vλ or Vκ gene segment. L

[0068] In one embodiment, the mouse comprises endogenous mouse heavy chain immunoglobulin genes

[0069] In one embodiment, the mouse comprises endogenous mouse heavy chain immunoglobulin genes

[0070] In one embodiment, the heavy chain constant region is an endogenous mouse heavy chain constant region.

[0071] In one embodiment, the mouse comprises endogenous mouse heavy chain immunoglobulin genes

[0072] In one embodiment, the mouse expresses an antigen binding protein comprising: (a) a polypeptide,

[0073] In one embodiment, the polypeptide comprises a Vλ or Vκ gene segment derived from a human,

[0074] In one aspect, a mouse is provided that contains in its germline a J gene segment identical to that of a human and a recombinant human J gene.

[0075] In one aspect, a mouse is provided that contains in its germline a J gene segment and a heavy chain

[0076] In one embodiment, the mouse comprises at least 6 unrearranged hVκ gene segments and

[0077] In one embodiment, the mouse exhibits a total of about 90% IgD + Cells and IgM +

[0078] In one aspect, a mouse is provided that expresses a modified endogenous heavy chain locus in its germline.

[0079] In one aspect, a mouse is provided that expresses an immunoglobulin, wherein the immunoglobulin

[0080] In one aspect, a mouse is provided that produces immune responses from unrearranged gene segments in its germline.

[0081] In one aspect, a mouse is provided that produces immune cells from unrearranged gene segments in its germline.

[0082] In one aspect, a mouse is provided, wherein the mouse is produced by producing a gene derived from the germline of the mouse without rearrangement

[0083] In one aspect, a mouse as described herein is provided, wherein the mouse comprises a gene selected from the group consisting of

[0084] In one aspect, a mouse embryo is provided, comprising a modified

[0085] In one aspect, a mouse or cell made with a nucleic acid construct described herein is provided.

[0086] In one aspect, a mouse made with the cells described herein is provided.

[0087] In one aspect, there is provided a method for producing a mouse encoding a second human light

[0088] In one aspect, there is provided a method for producing a mouse encoding a human immunoglobulin.

[0089] In one aspect, a method for producing a mouse encoding all or part of a

[0090] In one aspect, a method for producing a fully human Fab (comprising

[0091] In one aspect, methods for producing immortalized cell lines using mice as described herein are provided.

[0092] In one aspect, a method for producing hybridomas or quadrivalent tumors using the mice described herein is provided.

[0093] In one aspect, a cell is provided which comprises a modified immunoglobulin as described herein.

[0094] In one aspect, a cell is provided, comprising a nucleic acid sequence encoding a first polypeptide, wherein the second

[0095] In one embodiment, the cell further comprises a second polypeptide chain comprising

[0096] In one embodiment, the human Vκ or Vλ sequence of the first polypeptide is

[0097] In one embodiment, the Vκ or Vλ of the first polypeptide and the Vκ or Vλ of the second polypeptide

[0098] In one embodiment, the cell is selected from CHO cells, COS cells, 293

[0099] In one aspect, a mouse somatic cell is provided, which comprises a genetically modified

[0100] In one aspect, a mouse germ cell is provided, which comprises a genetically modified

[0101] In one aspect, provided are pluripotent, induced pluripotent

[0102] In one aspect, the cells described herein are used to produce mice, cells or therapeutic

[0103] In one aspect, a nucleic acid construct is provided, comprising a 23-mer spacer juxtaposed upstream and downstream.

[0104] In one aspect, a nucleic acid construct is provided, comprising a 12-mer spacer juxtaposed upstream of

[0105] In one aspect, a nucleic acid construct is provided, comprising a 23-mer spacer juxtaposed downstream of

[0106] In one embodiment, the nucleic acid construct comprises a human lambda light chain variable region sequence, which

[0107] In one embodiment, the nucleic acid construct comprises a human lambda light chain variable region sequence, which

[0108] In one embodiment, the nucleic acid construct comprises a human lambda light chain variable region sequence, which

[0109] In one embodiment, the human lambda light chain variable region sequence comprises at least one of cluster B.

[0110] In one aspect, a nucleic acid construct is provided, comprising a 23-mer spacer juxtaposed upstream and downstream.

[0111] In one aspect, a nucleic acid construct is provided, comprising a 23-mer spacer juxtaposed upstream and downstream.

[0112] In one aspect, a nucleic acid construct is provided, comprising a human Vλ or human Vκ segment, an upstream and

[0113] In one aspect, a targeting vector is provided, comprising: (a) a first targeting arm and a second targeting arm,

[0114] In one embodiment, the vector is directed to an endogenous or modified immunoglobulin gene

[0115] In one aspect, a nucleic acid construct as described herein is provided for use in making a mouse, a cell or

[0116] In one aspect, a nucleic acid sequence from a mouse as described herein is provided for use in making a cell

[0117] In one aspect, an expression system is provided, comprising a mammal transfected with a DNA construct

[0118] In one embodiment, the expression system further comprises a nucleotide sequence encoding

[0119] In one embodiment, the mammalian cell is selected from CHO cells, COS cells

[0120] In one aspect, a method for producing a binding protein is provided, the method comprising:

[0121] In one embodiment, the mouse is immunized with an antigen of interest, and the C H

[0122] In one embodiment, the suitable cell is selected from the group consisting of a B cell, a hybridoma, a tetravalent

[0123] In one embodiment, the C H The region comprises the human IgG isotype.

[0124] In one embodiment, the cell further comprises a protein encoding V L The nucleotide sequence of the domain,

[0125] In one aspect, a method for producing a genetically modified mouse is provided, the method comprising:

[0126] In one aspect, a method is provided for producing a mouse expressing a polypeptide comprising

[0127] In one aspect, a method for producing a genetically modified mouse as described herein is provided,

[0128] In one aspect, a method for making a modified mouse is provided, comprising:

[0129] In one aspect, an immunoglobulin variable region produced in a mouse as described herein is provided.

[0130] In one aspect, an immunoglobulin binding protein produced in a mouse as described herein is provided.

[0131] In one aspect, a light chain variable domain is provided, which is derived from a mouse as described herein.

[0132] In one aspect, an antibody or antigen-binding fragment thereof (e.g., Fab, F(ab) 2 , scFv), BRIEF DESCRIPTION OF THE DRAWINGS

[0133] Figure 1A A schematic diagram of the mouse heavy chain locus is depicted (not to scale).

[0134] Figure 1B A schematic representation of the human kappa light chain locus is depicted (not to scale).

[0135] Figure 2The stepwise insertion of 40 human Vκ and 5 human Jκ gene segments into mouse recombinant

[0136] Figure 3 A modified mouse heavy chain locus is shown, comprising a H Area Operational

[0137] Figure 4A The method for stepwise insertion of human Vλ and a single human Jλ gene segment into mouse heavy chain

[0138] Figure 4B The method for stepwise insertion of human Vλ and four human Jλ gene segments into mouse heavy chains is shown.

[0139] Figure 5A It shows that Vλ and D H Kazuto J H Gene segment insertion into mouse heavy chain

[0140] Figure 5B It shows that Vλ and D H and human Jκ gene segments were gradually inserted into mouse heavy chain

[0141] Fig. 6A Contour plots of splenocytes stained for surface expression of B220 and IgM are shown.

[0142] Figure 6B CD19 + Contour plot of splenocyte gating on B cells, the

[0143] Figure 6C Shown are the results for the wild-type (WT) and for the endogenous heavy chain locus.

[0144] Fig. 7A Shown are the results from wild-type mice (WT) and for the heavy chain locus placed at the endogenous

[0145] Figure 7B Shown are the results from wild-type mice (WT) and for the heavy chain locus placed at the endogenous

[0146] Figure 7C Shown are the results from wild-type mice (WT) and for the heavy chain locus placed at the endogenous

[0147] Fig.7D Shown are the results of a double-stranded analysis of the heavy chain locus from wild-type mice (WT) and for

[0148] Fig. 7E Shown are the results from wild-type mice (WT) and for the heavy chain locus placed at the endogenous

[0149] Figure 7FShown are the results from wild-type mice (WT) and for the heavy chain locus placed at the endogenous

[0150] Figure 7G Shown are the differences between wild type (WT) and for six genes placed at the endogenous heavy chain locus.

[0151] Fig. 8A Shown are the Igλ + and Igκ + Expression of staining,

[0152] Figure 8B Shown are the results of immunoblots isolated from the femurs of the following mice and stained for the expression of Igλ and Igκ:

[0153] Fig. 9 Thirty hVκ and five Jκ genes from the mouse heavy chain locus are shown. DETAILED DESCRIPTION OF THE INVENTION

[0155] The term "bispecific binding protein" includes proteins that are capable of selectively binding to two or more epitopes.

[0156] Thus, two general types of bispecific binding proteins are (1) V L 1-C H (dimer),

[0157] When used in relation to an expressed sequence, the term "cell" includes cells suitable for expressing a recombinant nucleic acid sequence.

[0158] When used in the sense of "cognate to..." (e.g. L Domain "homologous"

[0159] The phrase "complementarity determining region" or the term "CDR" includes the complementarity determining regions of an organism's immunoglobulin genes.

[0160] The term "gene segment" or "segment" includes reference to a V (light or heavy) or D or J (light or heavy) immune

[0161] The term "heavy chain" or "immunoglobulin heavy chain" includes immunoglobulins from any organism.

[0162] For example, and not by way of limitation, the heavy chain constant region may be modified to exhibit an increased

[0163] The term "light chain" includes immunoglobulin light chain constant (C L ) Area Sequence

[0164] The term "micromolar range" is intended to mean 1-999 micromolar; the term "nanomolar range" is intended to mean

[0165] The term "non-human animal" is intended to include any vertebrate, such as cyclostomes, bony fish,

[0166] Mouse, nucleotide sequence and binding protein

[0167] A binding protein encoded by an element of an immunoglobulin locus is provided, wherein the binding

[0168] The binding protein aspects described herein include a modified immunoglobulin locus

[0169] In the modified mice described herein, this gene that also contains the cognate light chain was produced.

[0170] In various embodiments, the modified mouse produces a binding protein comprising

[0171] In various embodiments, the binding protein comprises an immunoglobulin light chain sequence

[0172] In various embodiments, mice of the invention produce binding proteins that have an average

[0173] In another aspect, mice and methods are provided for providing a population of binding proteins comprising:

[0174] In other embodiments, mice according to the present invention can be made, wherein the mice weigh

[0175] In one aspect, methods are provided for increasing diversity, including by somatic hypermutation

[0176] In one embodiment, the hypermutated V L The fused immunoglobulin

[0177] In one embodiment, for a L sequence is operably linked to V L sequence

[0178] In one aspect, a method for producing a high affinity human V L Method for constructing a domain, the method

[0179] In one embodiment, the somatically mutated, class-switched

[0180] In one embodiment, the binding protein consists essentially of a polypeptide dimer,

[0181] In one embodiment, the binding protein is essentially composed of a polypeptide dimer and two light

[0182] In one aspect, a method for somatic hypermutation of human V L Method for gene sequencing, said method

[0183] In one embodiment, the method further comprises obtaining V from the mouse L Gene sequence

[0184] With D H Sequence V L Binding protein

[0185] In various aspects, comprising an unrearranged immunoglobulin light chain V gene segment and an unrearranged

[0186] In various aspects, a human light chain V segment comprising an unrearranged human D segment

[0187] Another source of diversity is N and / or P additions, which can be found in V(light chain) / J or V(light chain)

[0188] In various aspects, a light chain V gene segment operably linked to a J gene segment is used.

[0189] The RSS or recombination signal sequence contains a conserved nucleic acid heptamer sequence that is separated by 12 bases.

[0190] In the case of the lambda light chain locus, the variable gene segment (Vλ gene segment) is flanked downstream by

[0191] However, at the κ locus in wild-type organisms, each functional Vκ segment is located at the

[0192] In one embodiment, the heavy chain locus is associated with a J gene region having a Jλ segment.

[0193] In one embodiment, the heavy chain locus is Jκ or J H J

[0194] In one embodiment, the heavy chain locus is associated with D H gene segment and J gene segment

[0195] In one embodiment, the heavy chain locus is adjacent to the J gene segment (without intervening

[0196] In one embodiment, the heavy chain locus is used together with the D segment and the J segment.

[0197] The nucleic acid sequences can be prepared using any suitable method known in the art for preparing nucleic acid sequences.

[0198] The method of manufacturing the upstream and downstream

[0199] Suitable nonamers and heptamers for RSS construction are known in the art (see, e.g.,

[0200] Bispecific-binding proteins

[0201] The binding proteins described herein and the nucleotide sequences encoding them can be used to prepare

[0202] In one aspect, the methods and compositions described herein are used to make bispecific-binding proteins.

[0203] In one embodiment, the first V L Fusion C H IgG isotype

[0204] In one embodiment, the first C H The region comprises a region selected from IgG1, IgG2 and IgG4

[0205] In one embodiment, the second C H The 3 domain contains the 435R modification, the root

[0206] In one embodiment, the second C H The 3 domains are those of human IgG1, which contain

[0207] In one embodiment, the second C H The 3 domains are human IgG2, which contain

[0208] In one embodiment, the second C H The 3 domains are those of human IgG4, which contain

[0209] In one embodiment, the binding protein comprises one or more of the Example

[0210] The following examples are provided to describe how to make and use the methods and compositions of the present invention.

[0211] Embodiment 1

[0212] Introduction of light chain gene segments into the heavy chain locus

[0213] use

[0214] Briefly, recombinase-mediated recombination was used to delete small

[0215] Four separate targeting vectors were engineered to use standard molecules recognized in the art.

[0216] The approximately

[0217] Table 1

[0220] Ten additional human Vκ gene segments were introduced into the hybrid heavy chain locus.

[0221] Fourteen additional human Vκ gene segments were introduced into the hybrid heavy chain locus.

[0222] Ten additional human Vκ gene segments were introduced into the hybrid heavy chain locus.

[0223] Using a similar approach as described above, human heavy chain constant region in the context of the mouse

[0224] The human lambda light chain locus extends over 1,000 kb and contains more than 80 genes encoding variable (V)

[0225] Coupling light chain variable domains to heavy chain constant regions represents a potential source of diversity.

[0226] In addition, people D H and J H (or Jκ) gene segments can be integrated with human Vκ or Vλ gene segments

[0227] Therefore, the above strategy was used to integrate human kappa light chain gene segments into the endogenous heavy chain locus.

[0228] Example II

[0229] Identification of targeted ES cells carrying human light chain gene segments at the endogenous heavy chain locus

[0230] The targeted BAC DNA prepared in the above example was used to electroporate mouse ES

[0231] ES cells carrying human kappa light chain gene segments can be transfected with a construct expressing the recombinase.

[0232] Example III

[0233] Generation and analysis of expression V L Mouse binding protein

[0234] The targeted ES cells described above were used as donor ES cells and

[0235] Flow cytometry. In the F1 ES line (F1H4; Valenzuela et al., 2007, supra)

[0236] Briefly, blood was collected from groups of mice (n=6 / group) and crushed using slides.

[0237] In similar experiments, flow cytometry using multiple cell surface markers was performed.

[0238] Briefly, two groups (n=3, 8-week-old females) of wild-type and

[0239] Cells (1x10 6 ) Incubate very

[0240] After staining, cells were washed and fixed in 2% formaldehyde.

[0241] In similar experiments, flow cytometry using multiple cell surface markers was performed.

[0242] Briefly, two groups (n=3, 6-week-old females per group) containing the wild-type heavy chain locus were randomly assigned to

[0243] Cells (1× 10 6 ) on ice

[0244] After staining, cells were washed and fixed in 2% formaldehyde.

[0245] Isotype expression. Mice homozygous for the human heavy chain and kappa light chain variable gene loci

[0246] Briefly, mouse CD19 microbeads (Miltenyi Biotec) were used according to the manufacturer's instructions.

[0247] Table 2

[0249] Table 3

[0251] From quantitative

[0252] Human κ gene segment usage and Vκ-Jκ joining analysis.

[0253] Briefly, spleens were harvested and placed in sterile disposable bags with 10 mL of 5%

[0254] Primers specific for human hVκ gene segments and mouse IgG were used on spleen cell RNA

[0255] As shown in this example, for six human Vκ and five human Jκ gene segments homozygous

[0256] Table 4

[0259] Example IV

[0260] Breeding Expression V LMouse binding protein

[0261] In order to generate a new generation of V L Binding protein that can carry the unrearranged human κ gene segment

[0262] Alternatively, the expression of 5-mer can be enhanced by combining with a mouse strain that contains a deletion in one or more of the mouse light chain loci (κ and λ).

[0263] Mice carrying an unrearranged heterozygous heavy chain locus were also crossed with mice containing the human kappa light chain variable locus.

[0264] Example V

[0265] V L Production of binding proteins

[0266] When mice containing an unrearranged heterozygous heavy chain locus are crossed with mice containing other endogenous Ig loci,

[0267] Typically, antigen is used to stimulate cells containing at least one hybrid heavy chain locus.

[0268] Initially, the high affinity V L Binding protein having a human Vκ region and a mouse constant

[0269] Separate groups of mice were immunized with human cell-surface receptor protein (antigen X), the

[0270] When the desired immune response is achieved, spleen cells are harvested and mixed with mouse myeloma cells.

[0271] Alternatively, anti-antigen XV is isolated directly from antigen-positive B cells L Binding protein

[0272] The human kappa gene segment was used. To analyze the anti-antigen XV generated L Binding protein

[0273] Table 5

[0275] Enzyme-linked immunosorbent assay (ELISA). In the ELISA assay, the blocking antigen X

[0276] Briefly, ligand Y was coated on 96

[0277] The results showed that several V isolated from mice immunized with antigen X L Binding protein

[0278] Affinity determination. Using BIACORE TM T100 device (GE Healthcare),

[0279] Briefly, V was captured from crude supernatant samples on a CM5 sensor chip surface. L Knot

[0280] Thirty-four selected V L The binding affinities of binding proteins vary, all of which

[0281] In another experiment, Sequence Listing <110> Razerne Pharmaceuticals L. MacDonald S. Stevens C. Goole K.A. Hosiawa A.J. Murphy <120> Production of mice containing binding proteins containing the VL domain <130> 070860-8008CN03 <140> To be allocated <141> <150> 61 / 369,909 <151> 2010-08-02 <160> 29 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 1 gagaggaccg tggacaagtc 20 <210> 2 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 2 tgacggtggt gctgtagaag 20 <210> 3 <211> 28 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 3 atgctgagga ggaaggcttt gagaacct 28 <210> 4 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 4 gctcgtgagc aactgaacct 20 <210> 5 <211> 19 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 5 gccactgcac actgatgtc 19 <210> 6 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 6 agtcagccac agtcacctgc ctg 23 <210> 7 <211> 19 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 7 gcctgcacaa ccaccatac 19 <210> 8 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 8 gagcaggaag aggctgatga ag 22 <210> 9 <211> 25 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 9 agaagagcctctcccactctcctgg 25 <210> 10 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 10 cagccagcgg agaactacaa g 21 <210> 11 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 11 gcctcccagt tgctcttctg 20 <210> 12 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 12 aacactcagc ccatcatgga caca 24 <210> 13 <211> 19 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 13 tgagcagcac cctcacgtt 19 <210> 14 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 14 gtggcctcac aggtatagct gtt 23 <210> 15 <211> 18 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 15 accaaggacg agtatgaa 18 <210> 16 <211> 16 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 16 gtaaaacgac ggccag 16 <210> 17 <211> 17 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 17 caggaaacag ctatgac 17 <210> 18 <211> 145 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 18 tctggggacag aattcactct caccatcagc agcctgcagc ctgatgattt tgcaacttat 60 tactgccaac agtataatac cctcactttc ggcggaggga ccaaggtgga gatcaaaccc 120 aaaacaacag ccccatcggt ctatc 145 <210> 19 <211> 151 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 19 tctgggacag aatccactct cacaatcagc agcctgcagc ctgaagattt tgcaacttat 60 tactgtcaac agcttaatag ttaccctttc actttcggcg gagggaccaa ggtggagatc 120 aaacccaaaa caacagcccc atcggtctat c 151 <210> 20 <211> 151 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 20 tctgggacag atttcactct caccatcagc agcctgcagc ctgaagattt tgcaacttat 60 tactgccaac agtataatag ttaccctccc accttcggcc aagggacacg actggagatt 120 aaacctacaa caacagcccc atctgtctat c 151 <210> 21 <211> 153 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 21 tctgggacag atttcactct caccatcagc agcctgcagc ctgaagattt tgcaacttac 60 tattgtcaac aggctaacag tttcccgtac acttttggcc aggggaccaa gctggagatc 120 aaacccaaaa cgacaccccc atctgtctat cca 153 <210> 22 <211> 151 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 22 tctgggacag atttcactct caccatcagc agcctgcagc ctgaagatgt tgcaacttat 60 tactgtcaaa agtataacag tgcccctcac actttcggcg gagggaccaa ggtggagatc 120 aaacccaaaa caacagcccc atcggtctat c 151 <210> 23 <211> 153 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 23 tcaggcacag attttacact gaaaatcagc agagtggagg ctgaggatgt tggggtttat 60 tactgcatgc aagctctaca aatttcgtgg acgttcggcc aagggaccaa ggtggaaatc 120 aaacccaaaa cgacaccccc atctgtctat cca 153 <210> 24 <211> 150 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> twenty four tctggggacag acttcactct caccatcagc agcctagagc ctgaagattt tgcagtttat 60 tactgtcagc agcgtagccc ccgtttcact ttcggcggag ggaccaaggt ggagatcaaa 120 cccaaaacga cacccccatc tgtctatcca 150 <210> 25 <211> 148 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 25 tctggggacag acttcactct caccatcagc agactggagc ctgaagattt tgccgtgtat 60 tactgtcagc agtatggtag ctcactcact ttcggcggag ggaccaaggt ggagatcaaa 120 cccaaaacaa cagccccatc ggtctatc 148 <210> 26 <211> 151 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 26 tctggggacag atttcactct caccatcagc agcctgcagg ctgaagatgt ggcagtttat 60 tactgtcagc aatattatag tactccgatc accttcggcc aagggacacg actggagatt 120 aaacccaaaa caacagcccc atcggtctat c 151 <210> 27 <211> 151 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 27 tctggggacag atttcactct caccatcagc agcctgcagg ctgaagatgt ggcagtttat 60 tactgtcagc aatattatag tactgggccc acttttggcc aggggaccaa gctggagatc 120 aaacctacaa caacagcccc atctgtctat c 151 <210> 28 <211> 151 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 28 tatggaacag attttaccct cacaattaat aacattgaat gtgaggatgc tgcatattac 60 ttctgtctac aacatgataa tttcccgtac acttttggcc aggggaccaa gctggagatc 120 aaacccaaaa caacagcccc atcggtctat c 151 <210> 29 <211> 147 <212> DNA <213> Artificial sequence <220> <223> Synthetic <400> 29 tatggaacag attttaccct cacaattaat aacatagaat ctgaggatgc tgcatattac 60 ttctgtctac aacatgataa ttggacgttc ggccaaggga ccaaggtgga aatcaaaccc 120 aaaacgacac ccccatctgt ctatcca 147

Claims

1. A targeting vector comprising: (a) a first targeting arm and a second targeting arm, wherein the first targeting arm and the second targeting arm direct the targeting vector to an endogenous mouse immunoglobulin heavy chain locus; and (b) a contiguous sequence comprising: Unrearranged people V L Gene segments and unrearranged human J L Gene segment, wherein homologous recombination with the targeting vector produces a hybrid immunoglobulin locus comprising: The unrearranged human V L Gene segments and the unrearranged human J L The gene segments are operably linked to an endogenous immunoglobulin heavy chain constant region nucleic acid sequence at an endogenous mouse immunoglobulin heavy chain locus.

2. The targeting vector of claim 1, wherein: The unrearranged human V L The gene segment comprises a human κ segment, a human λ gene segment, or a combination thereof, The endogenous immunoglobulin heavy chain constant region nucleic acid sequence is selected from the group consisting of: H 1 sequence, hinge sequence, C H 2 sequence, C H 3 sequences and their combinations, After homologous recombination, the unrearranged human V L Gene segments and the unrearranged human J L The gene segments replace the endogenous heavy chain variable V H Gene segments and endogenous heavy chain J H segment, wherein the unrearranged human V L Gene segments and the unrearranged human J L The gene segments replace all functional rodent heavy chain V H , D H and J H Gene segment, The unrearranged human V L The gene segment only comprises human Vκ gene segments, and the unrearranged human J L The gene segment is the human Jκ gene segment, The targeting vector comprises at least six or more unrearranged human V L Gene segments and the unrearranged human J L Gene segment, The contiguous sequence is selected from the group consisting of: (i) hVκ4-1 to hVκ1-6 and Jκ1, (ii) hVκ4-1 to hVκ1-6 and Jκ1 to Jκ2, (iii) hVκ4-1 to hVκ1-6 and Jκ1 to Jκ3, (iv) hVκ4-1 to hVκ1-6 and Jκ1 to Jκ4, (v) hVκ4-1 to hVκ1-6 and Jκ1 to Jκ5, (vi) hVκ3-7 to hVκ1-16, (vii) hVκ1-17 to hVκ2-30, (viii) hVκ3-31 to hVκ2-40, and (ix) combinations thereof, The hybrid immunoglobulin locus lacks the unrearranged human V L Gene segments and the unrearranged human J L Any functional heavy chain D between gene segments H Segment, and / or Each of the unrearranged human V L Gene segments and the unrearranged human J L The gene segment comprises a recombination signal sequence that allows the unrearranged human V L Gene segments and the unrearranged human J L The gene segments recombine to form rearranged human immunoglobulin light chain variable regions (V L / J L ) nucleotide sequence, the rearranged human immunoglobulin light chain variable region (V L / J L ) nucleotide sequence is connected to the endogenous immunoglobulin heavy chain constant region nucleic acid sequence at the endogenous mouse immunoglobulin heavy chain locus.

3. A mouse cell comprising the targeting vector of claim 1. The mouse cell of claim 3 , wherein the mouse cell is a mouse ES cell.

5. The mouse cell of claim 3, wherein the mouse cell is a mouse B cell.

6. A method for making a genetically modified mouse comprising in its germline at least one unrearranged human immunoglobulin light chain variable region (V LCR) operably linked to a heavy chain constant region nucleic acid sequence. L ) gene segment and at least one unrearranged human immunoglobulin light chain (J L ) gene segment, the method comprising: (a) modifying a totipotent mouse cell to include the targeting vector of claim 1 by homologous recombination, such that the totipotent mouse cell comprises a hybrid immunoglobulin locus comprising the unrearranged human V constant region operably linked to an endogenous immunoglobulin heavy chain constant region nucleic acid sequence at an endogenous mouse immunoglobulin heavy chain locus. L Gene segments and the unrearranged human J L Gene segment; (b) maintaining the totipotent mouse cell under suitable conditions to develop into a genetically modified mouse comprising the hybrid immunoglobulin locus in its germ line.

7. A mouse genome comprising the targeting vector of claim 1.

8. The mouse genome of claim 7, wherein the mouse genome comprises the targeting vector of claim 1 at an endogenous immunoglobulin heavy chain locus.

9. The mouse genome of claim 8, wherein an endogenous immunoglobulin heavy chain regulatory element is operably linked to the contiguous sequence.

10. A method for obtaining a nucleotide sequence encoding a light chain variable domain, the method comprising obtaining a nucleic acid encoding a hybrid heavy chain from a lymphocyte of a mouse or from a hybridoma produced by the lymphocyte, the hybrid heavy chain comprising the light chain variable domain (V L ... L ), The mouse comprises in its germline at least one unrearranged light chain variable (V L ) gene segment and at least one unrearranged light chain junction (J L ) gene segment, wherein wherein the rearranged hybrid heavy chain gene encodes the hybrid heavy chain capable of associating with an immunoglobulin light chain.

11. A cell comprising the nucleotide sequence obtained according to the method of claim 10.

12. Immunoglobulin produced by the cell of claim 11.

13. A hybrid immunoglobulin heavy chain produced by a genetically modified mouse, wherein the genetically modified mouse comprises in its germline at least one unrearranged immunoglobulin light chain variable (V LCH) operably linked to an immunoglobulin heavy chain constant region nucleotide sequence. L ) gene segment and at least one unrearranged immunoglobulin light chain (J L ) gene segment, wherein the unrearranged immunoglobulin V L and J L The gene segments each comprise a recombination signal sequence such that the at least one unrearranged immunoglobulin V L gene segment and the at least one unrearranged immunoglobulin J L The gene segments are recombined to form a variable region sequence operably linked to the immunoglobulin heavy chain constant region nucleic acid sequence to form a rearranged hybrid heavy chain gene, wherein the rearranged hybrid heavy chain gene encodes the hybrid immunoglobulin heavy chain comprising the V domain linked to an immunoglobulin heavy chain constant domain L domain, and Wherein the hybrid immunoglobulin heavy chain is capable of associating with an immunoglobulin light chain.